Ohio State University
Latest From Ohio State University
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more...
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.